Drug intelligence / Profile preview

ICP-033

Development stage: Phase 1
Lead developer: InnoCare Pharma
Modality: Small Molecules
Administration: Oral

Overview

ICP-033 is an orally bioavailable, multi-kinase inhibitor developed by InnoCare Pharma for the treatment of advanced solid tumors. It primarily targets the Vascular Endothelial Growth Factor Receptor (VEGFR), Fibroblast Growth Factor Receptor (FGFR), and Colony Stimulating Factor 1 Receptor (CSF-1R). By inhibiting these pathways, ICP-033 aims to suppress tumor angiogenesis, inhibit tumor cell proliferation, and modulate the tumor microenvironment by reducing immunosuppressive myeloid cells. It is currently being evaluated in Phase I clinical trials to assess its safety, tolerability, and pharmacokinetics in patients with various solid tumors.

Targets

CSF1R (Macrophage colony-stimulating factor receptor)FGFR (FGFR family)VEGFR (VEGFR family)

Beyond the preview

Go deeper on ICP-033.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICP-033.

Explore the full profile